Estimating population immunity against serotype-two poliomyelitis from the inactivated polio vaccine in routine immunization across 112 countries: A modelling study
PLOS Medicine · 19.03.2026 · 23 (3) · e1004952
DOI: 10.1371/journal.pmed.1004952 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Medicine, online erschienen am 19.03.2026. Verfasst von Elizabeth J Gray und 6 weiteren Autor:innen. Beteiligte Einrichtung: MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom. Hauptthemen laut MEDLINE: Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Medical Research Council.
Abstract (Originalsprache)
Background To mitigate the risk of outbreaks of serotype 2 poliomyelitis after withdrawal of this serotype from oral poliovirus vaccine (OPV) in 2016, inactivated poliovirus vaccine (IPV) was introduced into the routine immunization (RI) programmes of all countries using OPV. Since 2022, WHO has recommended a 2-dose schedule, with a first dose at 14 weeks of age followed by a second dose at least 4 months later (e.g., 14–39 week schedule), although an earlier schedule may be adopted, despite lower immunogenicity, if vaccine coverage is low at older ages. Methods and findings We combined published data on type-2 IPV seroconversion with age, national RI coverage estimates, dose introduction dates, and country-specific schedules using a cohort model of population immunity to estimate IPV-induced immunity from 2024–2031 for 112 countries using either one or two doses of IPV. We projected immunity for current, 6–14, and 14–39 week schedules to find the optimal schedule and estimate the impact of interventions such as schedule changes and catch-ups. Under current schedules, estimated median serotype 2 population immunity in 2025 among children under five years of age is at 61% (IQR: 52%, 72%), rising to 71% (IQR: 57%, 80%) in 2031. The later 14–39 week schedule was optimal in all countries, with potential for the median immunity to rise to 78% (IQR: 66%, 85%) by 2031 if adopted by all countries in 2026. Eight countries would still have
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.
- Expanded Programme on Immunization, Vaccines, and Biologicals Department, World Health Organization, Geneva, Switzerland.
- Polio Eradication Department, World Health Organization, Geneva, Switzerland.
ORCID-Profile: Elizabeth J Gray, Alejandro Ramirez Gonzalez, Isobel M Blake
Förderung
- World Health Organization
- Medical Research Council
Zitieren
APA
Gray, E. J., Cooper, L. V., Gonzalez, A. R., Mach, O., Derqui, N., Grassly, N. C., & Blake, I. M. (2026). Estimating population immunity against serotype-two poliomyelitis from the inactivated polio vaccine in routine immunization across 112 countries: A modelling study. PLOS Medicine, 23(3), e1004952. https://doi.org/10.1371/journal.pmed.1004952
Vancouver
Gray EJ, Cooper LV, Gonzalez AR, Mach O, Derqui N, Grassly NC, et al. Estimating population immunity against serotype-two poliomyelitis from the inactivated polio vaccine in routine immunization across 112 countries: A modelling study. PLOS Medicine. 2026;23(3):e1004952. doi:10.1371/journal.pmed.1004952
BibTeX
@article{Gray2026,
author = {Gray, Elizabeth J and Cooper, Laura V and Gonzalez, Alejandro Ramirez and Mach, Ondrej and Derqui, Nieves and Grassly, Nicholas C and Blake, Isobel M},
title = {Estimating population immunity against serotype-two poliomyelitis from the inactivated polio vaccine in routine immunization across 112 countries: A modelling study},
journal = {PLOS Medicine},
year = {2026},
volume = {23},
number = {3},
pages = {e1004952},
doi = {10.1371/journal.pmed.1004952}
}
EUVIMED